{'fraction_non_alphanumeric': 0.03156146179401993, 'fraction_numerical': 0.023255813953488372, 'mean_word_length': 5.216494845360825, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Enhanced chemotherapeutic efficacy on carcinomatous peritonitis using a new dosage form in animal experiments.

A new dosage form, comprising Mitomycin C adsorbed on activated carbon particles (MMC-CH) was studied for its local therapeutic effects on carcinomatous peritonitis. After intraperitoneal transplantation of 10(7) cells of Yoshida sarcoma, drug treatment was given on day 2. The ED50 value on ascites was determined with Litchfield-Wilcoxon's method on day 6. The therapeutic index (LD50/ED50) on ascites in MMC-CH treatment was 3.09 times higher than that in Mitomycin C solution treatment.